1. Rights Issue - debt-free balance sheet - The ₹129.90 crore rights issue closed in October 2025, with proceeds fully repaying all term debt and parent loans, bringing the debt-equity ratio to zero from 1.05. Finance costs halved to ₹503 lakhs in FY26 from ₹910 lakhs in FY25, directly lifting net profit which more than doubled year-on-year.
2. Antioxidant and Ethoxylates capacity expansion - Installed capacity rose to 25,231 MTPA in FY25 from 18,067 MTPA in FY24, with the expanded Antioxidant plant and debottlenecked Ethoxylates/Theic units operational from early Q2FY25. Capacity utilisation was below 80% in FY25 as new lines stabilised, leaving a clear volume ramp-up path that drove the 29% YoY sales volume growth already recorded.
3. Volume-led revenue ramp - Revenue grew 20.54% YoY to ₹44,091 lakhs in FY26, with domestic revenue up 22.92%, supported by healthy order flows from existing and new customers. India Ratings expected 20-22% revenue growth in FY26 driven by increasing utilisation of the newly added capacity, and 9MFY26 revenues had already reached ₹331.24 crore.
4. Zero-debt capex model going forward - Management has stated that ongoing capex and operational-efficiency investments are non-debt-funded, with no debt-led capex plan and no term-debt repayment obligations remaining. Capital work-in-progress fell sharply to ₹579 lakhs as at March 2026 from ₹3,459 lakhs in FY25, signalling that the heavy investment cycle is largely complete and future free cash flow should improve.
5. Ethoxylates and Antioxidants pricing strength - Strong growth in Ethoxylates and Antioxidant-based products was driven by higher demand and improved pricing, while Ethoxylates, Propoxylates and Theic-based products achieved higher price realisation on similar volumes. Better realisations in these core product lines directly support the margin improvement already visible in FY26 results.
6. Global sourcing shift toward India - The company is positioned to benefit as global multinationals seek alternative suppliers amid geopolitical disruptions, with India's specialty chemicals market share expected to grow to 6% by 2026 from 3-4% in fiscal 2021. Export sales were ₹5,985 lakhs in FY26, and the company already serves customers across the Americas, Europe and the Far East.
7. Import substitution through in-house R&D - R&D efforts have resulted in the import substitution of one product developed by the company's R&D department. A successful import-substitute product creates a captive demand base and reduces dependence on external suppliers, with potential to scale across the existing customer network in plastics, rubber and lubricants.